Literature DB >> 8043041

Location of CD4 dimerization site explains critical role of CDR3-like region in HIV-1 infection and T-cell activation and implies a model for complex of coreceptor-MHC.

J P Langedijk1, W C Puijk, W P van Hoorn, R H Meloen.   

Abstract

CD4 cross-linking by antibodies or its natural ligands triggers a tyrosine kinase activity that is one of the necessary steps in the mechanism of human immunodeficiency virus type 1 (HIV-1)-induced syncytium formation and full Th-cell activation. In this study we mapped a part of the dimerization site of human CD4 to amino acids 87-98 using a bivalent CD4 immunoadhesin and a series of overlapping 12-mer peptides of the D1 domain. The dimerization site we found is part of the complementary determining region (CDR) 3-like region of CD4. Using the three-dimensional structure of other immunoglobulin dimers as a basis, a molecular modeling study was performed to dimerize the D1 domains of CD4. Both the peptide binding studies and molecular modeling studies independently led to the conclusion that the CDR3-like region is part of the CD4 dimerization site. The suggested dimerization of CD4 through its CDR3-like region explains the important role that has been ascribed to this region in Th-cell activation and HIV-1-mediated fusion. Based on this model of the CD4 dimer and published results of different mutational analysis studies, a model was proposed for the complex of the CD4 dimer with two MHC-II molecules. The CD4 dimer allows tight binding to a large surface of MHC-II and the complex of CD4 and MHC-II reconciles mutational analysis studies that were previously incompatible. Moreover, the complex suggests how CD4 can dimerize through ligand binding.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8043041

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

1.  Postbinding events mediated by human immunodeficiency virus type 1 are sensitive to modifications in the D4-transmembrane linker region of CD4.

Authors:  S Moir; J Perreault; L Poulin
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

2.  Modulation of CD4 lateral mobility in intact cells by an intracellularly applied antibody.

Authors:  K Grebenkämper; P F Tosi; J E Lazarte; L Sneed; U Brüggemann; U Kubitscheck; C Nicolau; R Peters
Journal:  Biochem J       Date:  1995-11-15       Impact factor: 3.857

3.  Molecular and cellular analysis of human immunodeficiency virus-induced apoptosis in lymphoblastoid T-cell-line-expressing wild-type and mutated CD4 receptors.

Authors:  L Moutouh; J Estaquier; D D Richman; J Corbeil
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

Review 4.  Structure-based design of immunologically active therapeutic peptides.

Authors:  R Murali; M I Greene
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

5.  A computer screening approach to immunoglobulin superfamily structures and interactions: discovery of small non-peptidic CD4 inhibitors as novel immunotherapeutics.

Authors:  S Li; J Gao; T Satoh; T M Friedman; A E Edling; U Koch; S Choksi; X Han; R Korngold; Z Huang
Journal:  Proc Natl Acad Sci U S A       Date:  1997-01-07       Impact factor: 11.205

6.  Functional epitope analysis of the human CD4 molecule: antibodies that inhibit human immunodeficiency virus type 1 gene expression bind to the immunoglobulin CDR3-like region of CD4.

Authors:  M Benkirane; M Hirn; D Carrière; C Devaux
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

7.  Cross-linking of CD4 in a TCR/CD3-juxtaposed inhibitory state: a pFRET study.

Authors:  G Szabó; J L Weaver; P S Pine; P E Rao; A Aszalos
Journal:  Biophys J       Date:  1995-03       Impact factor: 4.033

8.  Association between disruption of CD4 receptor dimerization and increased human immunodeficiency virus type 1 entry.

Authors:  Rachel Bourgeois; Johanne Mercier; Isabelle Paquette-Brooks; Eric A Cohen
Journal:  Retrovirology       Date:  2006-06-08       Impact factor: 4.602

9.  Interaction between CD8 and major histocompatibility complex (MHC) class I mediated by multiple contact surfaces that include the alpha 2 and alpha 3 domains of MHC class I.

Authors:  J Sun; D J Leahy; P B Kavathas
Journal:  J Exp Med       Date:  1995-11-01       Impact factor: 14.307

10.  Basic aspects of immunomodulation through active immunization.

Authors:  R H Meloen
Journal:        Date:  2000-03-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.